Literature DB >> 23847193

Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.

Shuju Feng1, Stephen J Eyler, Yuzhou Zhang, Tara Maga, Carla M Nester, Michael H Kroll, Richard J Smith, Vahid Afshar-Kharghan.   

Abstract

Complement dysregulation leads to atypical hemolytic uremic syndrome (aHUS), while ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura. We investigated whether genetic variations in the ADAMTS13 gene partially explain the reduced activity known to occur in some patients with aHUS. We measured complement activity and ADAMTS13 function, and completed mutation screening of multiple complement genes and ADAMTS13 in a large cohort of aHUS patients. In over 50% of patients we identified complement gene mutations. Surprisingly, 80% of patients also carried at least 1 nonsynonymous change in ADAMTS13, and in 38% of patients, multiple ADAMTS13 variations were found. Six of the 9 amino acid substitutions in ADAMTS13 were common single nucleotide polymorphisms; however, 3 variants-A747V, V832M, and R1096H- were rare, with minor allele frequencies of 0.0094%, 0.5%, and 0.32%, respectively. Reduced complement and ADAMTS13 activity (<60% of normal activity) were found in over 60% and 50% of patients, respectively. We concluded that partial ADAMTS13 deficiency is a common finding in aHUS patients and that genetic screening and functional tests of ADAMTS13 should be considered in these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23847193      PMCID: PMC3750341          DOI: 10.1182/blood-2013-03-492421

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians.

Authors:  T N Bongers; M P M De Maat; D W J Dippel; A G Uitterlinden; F W G Leebeek
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

2.  Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation.

Authors:  Barbara Plaimauer; Jakob Fuhrmann; Gabriele Mohr; Waltraud Wernhart; Katharina Bruno; Silvia Ferrari; Christian Konetschny; Gerhard Antoine; Manfred Rieger; Friedrich Scheiflinger
Journal:  Blood       Date:  2005-09-13       Impact factor: 22.113

3.  Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.

Authors:  Z Tao; K Anthony; Y Peng; H Choi; L Nolasco; L Rice; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2006-06-22       Impact factor: 5.824

4.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.

Authors:  Tomoko Ono; Jun Mimuro; Seiji Madoiwa; Kenji Soejima; Yuji Kashiwakura; Akira Ishiwata; Katsuhiro Takano; Tsukasa Ohmori; Yoichi Sakata
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

5.  FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.

Authors:  Koichi Kokame; Yuko Nobe; Yoshihiro Kokubo; Akira Okayama; Toshiyuki Miyata
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

6.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

7.  Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas.

Authors:  A Tripodi; V Chantarangkul; M Böhm; U Budde; J-F Dong; K D Friedman; M Galbusera; J-P Girma; J Moake; M E Rick; J-D Studt; P L Turecek; P M Mannucci
Journal:  J Thromb Haemost       Date:  2004-09       Impact factor: 5.824

8.  Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate.

Authors:  Miguel A Cruz; Jody Whitelock; Jing-fei Dong
Journal:  Thromb Haemost       Date:  2003-12       Impact factor: 5.249

9.  Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.

Authors:  Antonella Lattuada; Edoardo Rossi; Cinzia Calzarossa; Rosaria Candolfi; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2003-09       Impact factor: 9.941

10.  Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement.

Authors:  Marina Noris; Sara Bucchioni; Miriam Galbusera; Roberta Donadelli; Elena Bresin; Federica Castelletti; Jessica Caprioli; Simona Brioschi; Friedrich Scheiflinger; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2005-03-30       Impact factor: 10.121

View more
  34 in total

1.  von Willebrand factor is a cofactor in complement regulation.

Authors:  Shuju Feng; Xiaowen Liang; Michael H Kroll; Dominic W Chung; Vahid Afshar-Kharghan
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

2.  The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Kejian Zhang; Fanggeng Zou; Benjamin Laskin; Christopher E Dandoy; Kasiani C Myers; Adam Lane; Jaroslav Meller; Mario Medvedovic; Jenny Chen; Stella M Davies
Journal:  Blood       Date:  2015-11-24       Impact factor: 22.113

3.  Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab.

Authors:  Appalanaidu Sasapu; Michele Cottler-Fox; Pooja Motwani
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

4.  Eculizumab cessation in atypical hemolytic uremic syndrome.

Authors:  Samuel A Merrill; Zachary D Brittingham; Xuan Yuan; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal:  Blood       Date:  2017-05-01       Impact factor: 22.113

Review 5.  Atypical hemolytic uremic syndrome.

Authors:  Vahid Afshar-Kharghan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  Von Willebrand factor regulates complement on endothelial cells.

Authors:  Damien G Noone; Magdalena Riedl; Fred G Pluthero; Mackenzie L Bowman; M Kathryn Liszewski; Lily Lu; Yi Quan; Steve Balgobin; Reinhard Schneppenheim; Sonja Schneppenheim; Ulrich Budde; Paula James; John P Atkinson; Nades Palaniyar; Walter H A Kahr; Christoph Licht
Journal:  Kidney Int       Date:  2016-05-25       Impact factor: 10.612

Review 7.  Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure.

Authors:  Bradley S Podd; Dennis W Simon; Santiago Lopez; Andrew Nowalk; Rajesh Aneja; Joseph A Carcillo
Journal:  Pediatr Clin North Am       Date:  2017-08-18       Impact factor: 3.278

Review 8.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

9.  Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.

Authors:  Cynthia M Magro; Shabnam Momtahen; Joseph Justin Mulvey; Aminah H Yassin; Robert B Kaplan; Jeffrey C Laurence
Journal:  Am J Dermatopathol       Date:  2015-05       Impact factor: 1.533

10.  Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Authors:  Evgeny Arons; Sharon Adams; David J Venzon; Ira Pastan; Robert J Kreitman
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.